Latest News
Cardiff Oncology, Inc.
- Cardiff Oncology, Inc. Estimates – NASDAQ:CRDF
- Cardiff Oncology Holders Approve Doubling Authorized Common Stock to 300 Million Shares
- FDA grants orphan drug status to Cardiff’s onvansertib for CMML By Investing.com
- FDA grants orphan drug status to Cardiff Oncology's onvansertib for CMML
- Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
- Cardiff Oncology's Onvansertib Gains FDA Orphan Drug Status, Tic
- CRDF Q2 2026 Earnings: Narrower-Than-Expected Loss as Cardiff Oncology Advances Clinical-Stage Pipeline - Revenue Breakdown Analysis
Headlines from the last 30 days, linking to the original publishers. See all market news →